TrialSignal
Clinical trial intelligence report
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT06461624-Jul 28, 2026
NCT ID
NCT06461624
Status
RECRUITING
Phase
PHASE1
Sponsor
Zhejiang University
Executive brief
Investment-Ready Snapshot
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma is a PHASE1 clinical asset sponsored by Zhejiang University in Advanced Hepatocellular Carcinoma. SEO and diligence focus: anti-GPC3 CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06461624
Indication
Advanced Hepatocellular Carcinoma
Modality
cell therapy
Target
anti-GPC3 CAR-T
Intervention
anti-GPC3 CAR-T
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.